DOIONLINE 
DOIONLINE Publish In |
International Journal of Advances in Science, Engineering and Technology(IJASEAT)-IJASEAT |
 Journal Home Volume Issue |
||||||||
Issue |
Volume-5, Issue-4 ( Oct, 2017 ) | |||||||||
Paper Title |
Off-Label use of Apremilast for Autoimmune Skin Disorders Treatment | |||||||||
Author Name |
Dian Novita Sari, Lintang Indra Sukmawati, Tazkia Fitriani | |||||||||
Affilition |
Faculty of Pharmacy, Universitas Airlangga, Surabaya-Indonesia | |||||||||
Pages |
17-20 | |||||||||
Abstract |
“Off-label use” refers to when a medication is prescribed for a use or in a way that has not been approved by the Food and Drug Administration. Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that can be used off-label for autoimmune skin disorder treatment such as pyoderma gangrenosum, Behc et’s disease, and neutropholic ulcerative dermatosis. The primary goal of this study is to discuss about off-label use of apremilast for autoimmune skin disorders treatment so that researchers can enhance their knowledge about off-label use of apremilast that certainly required to treat autoimmune skin disorders. Autoimmune skin disorders occur worldwide and affected individuals in everyday life because of the discomfort caused by skin lesion. The method of this paper was through reviewing of published research datas and books that focused on off-label use of apremilast for autoimmune skin disorders treatment. The result indicates that off-label use of apremilast is an effective medication to decrease the intense inflammation of skin lesion. In conclusion, this paper describes apremilast as a potential off-label drug for autoimmune skin disorders treatment where the safety and efficacy of medications are needed. Keywords - Apremilast, Autoimmune skin disorder, Off-label use, Therapeutics | |||||||||
| View Paper | ||||||||||
